NCT06193135View on ClinicalTrials.gov

Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)

NARecruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Infertility, FemaleReproductive Sterility
Interventions
DRUG

Corifolitropin Alfa

Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.

DRUG

Folitropin Beta

Patient will receive daily dose of Folitropin Beta since triggering criteria are met.

Trial Locations (2)

46015

RECRUITING

IVI Valencia, Valencia

RECRUITING

Ivi Valencia, Valencia

All Listed Sponsors
lead

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

NCT06193135 - Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) | Biotech Hunter | Biotech Hunter